HPV-Negative Adenocarcinomas of the Uterine Cervix: From Molecular Characterization to Clinical Implications

被引:38
作者
Giannella, Luca [1 ]
Di Giuseppe, Jacopo [1 ]
Delli Carpini, Giovanni [1 ]
Grelloni, Camilla [1 ]
Fichera, Mariasole [1 ]
Sartini, Gianmarco [1 ]
Caimmi, Serena [1 ]
Natalini, Leonardo [1 ]
Ciavattini, Andrea [1 ]
机构
[1] Polytech Univ Marche, Womans Hlth Sci Dept, Gynecol Sect, I-60123 Ancona, Italy
关键词
adenocarcinoma; cervix; HPV; HPV-negative; therapy; molecular basis; gene mutations; CLEAR-CELL ADENOCARCINOMA; ENDOCERVICAL GLANDULAR HYPERPLASIA; GASTRIC-TYPE ADENOCARCINOMA; MINIMAL DEVIATION ADENOCARCINOMA; DIFFERENT HISTOLOGICAL SUBTYPES; RISK HUMAN-PAPILLOMAVIRUS; RECURRENT KRAS MUTATIONS; IN-UTERO; MESONEPHRIC ADENOCARCINOMAS; RADICAL HYSTERECTOMY;
D O I
10.3390/ijms232315022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cervical cancer is the fourth most common cancer in women. It is the leading cause of female deaths in developing countries. Most of these cervical neoplasms are represented by squamous lesions. Cervical adenocarcinoma causes about a quarter of cervical cancers. In contrast to squamous lesions, cervical glandular disease is HPV-negative in about 15-20% of cases. HPV-negative cervical adenocarcinomas typically present in advanced stages at clinical evaluation, resulting in a poorer prognosis. The overall and disease-free survival of glandular lesions is lower than that of squamous lesions. Treatment options require definitive treatments, as fertility-sparing is not recommended. Moreover, the impact of HPV vaccination and primary HPV screening is likely to affect these lesions less; hence, the interest in this challenging topic for clinical practice. An updated review focusing on clinical and molecular characterization, prognostic factors, and therapeutic options may be helpful for properly managing such cervical lesions.
引用
收藏
页数:20
相关论文
共 124 条
[1]  
Adani-Ife Ablavi, 2015, Gynecol Oncol Res Pract, V2, P3, DOI 10.1186/s40661-015-0010-5
[2]   Clear cell adenocarcinoma of the cervix in a child without in utero exposure to diethylstilbestrol:: A case report and review of the literature [J].
Ahrens, WA ;
Barrón-Rodriguez, L ;
McKee, MP ;
Rivkees, S ;
Reyes-Múgica, M .
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 2005, 8 (06) :690-695
[3]   Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study [J].
An, HJ ;
Kim, KR ;
Kim, IS ;
Kim, DW ;
Park, MH ;
Park, IA ;
Suh, KS ;
Seo, EJ ;
Sung, SH ;
Sohn, JH ;
Yoon, HK ;
Chang, ED ;
Cho, HI ;
Han, JY ;
Hong, SR ;
Ahn, GH .
MODERN PATHOLOGY, 2005, 18 (04) :528-534
[4]  
[Anonymous], 2002, INT J GYNECOL OBSTET, V78, P79
[5]  
[Anonymous], 2022, NCCN GUID CERV CANC
[6]   Distinction of endocervical and endometrial adenocarcinomas - Immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection [J].
Ansari-Lari, MA ;
Staebler, A ;
Zaino, RJ ;
Shah, KV ;
Ronnett, BM .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (02) :160-167
[7]   Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix [J].
Baalbergen, A. ;
Veenstra, Y. ;
Stalpers, L. L. ;
Ansink, A. C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01)
[8]   Identification and characterization of HPV- independent cervical cancers [J].
Banister, Carolyn E. ;
Liu, Changlong ;
Pirisi, Lucia ;
Creek, Kim E. ;
Buckhaults, Phillip J. .
ONCOTARGET, 2017, 8 (08) :13375-13386
[9]   Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices [J].
Blatt, Amy J. ;
Kennedy, Ronald ;
Luff, Ronald D. ;
Austin, R. Marshall ;
Rabin, Douglas S. .
CANCER CYTOPATHOLOGY, 2015, 123 (05) :282-288
[10]   Clinicopathological characteristics of patients with mucinous adenocarcinoma of the uterine cervix: A retrospective study of 21 cases [J].
Bonin, Lucie ;
Devouassoux-Shisheboran, Mojgan ;
Golfier, Francois .
JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2019, 48 (05) :319-327